Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
A bad night of sleep was associated with a 15% greater risk of having an atrial fibrillation (A-Fib) episode the following day, along with conditions like blood clots, heart failure, stroke and other heart-related problems.
Two sisters are receiving a breakthrough, FDA-approved treatment for beta thalassemia at UCSF Benioff Children's Hospital, Oakland. This is the first real therapy other than monthly transfusions for a devastating disease that destines people to shorter lives.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
UCSF Benioff Children’s Hospital Oakland is the first hospital in the West to administer a newly approved gene therapy to treat beta thalassemia with gene therapy, reducing the need for lifelong blood transfusions.